Standard BioTools Inc. (LAB)
NASDAQ: LABIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LAB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $249.11M
- EPS (TTM)
- -$0.09
- Dividend yield
- None
- 52-week range
- 0.39 – 1.72
- Day range
- 0.5729 – 0.65
- Volume / Avg
- 2.81M / 1.16M
- Beta
- —
- Shares outstanding
- 394.79M
52-week range
LAB stock today
Standard BioTools (LAB) closed at $0.631 on Nov 20, up 2.82% (+$0.0173), versus the S&P 500's 3.70% decline. Volume was 2.4x the average at 2.81M shares, a sign of unusually heavy trading. Shares are 63.3% below their 52-week high of $1.72, set on Dec 22, 2025 and 61.8% above the 52-week low of $0.39, near the bottom of the past year's range.
LAB is down 50.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 54.3%. Standard BioTools has posted a net loss over the last twelve months (EPS of -$0.09), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Standard BioTools
Company profileStandard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses.
- Sector
- Industrials
- Industry
- Biotechnology: Laboratory Analytical Instruments
- CEO
- Dr. Michael Egholm Ph.D.
- Headquarters
- Boston, MA
- Employees
- 385
- IPO year
- 2011
- Website
- standardbio.com
Financial highlights
Full financialsIn fiscal 2025, Standard BioTools generated $85.3 million in revenue, down 6.2% from fiscal 2024, its first annual decline since 2024. Standard BioTools reported a net loss of $74.9 million, compared with a loss of $138.9 million a year earlier. Gross margin was 49.9% (up from 49.3%) and operating margin -129.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $85.33M | $91.01M | $106.34M | $97.95M | $130.58M |
| Growth | -6.24% | -14.42% | +8.57% | -24.99% | -5.47% |
| Net income | $-74.90M | $-138.88M | $-74.66M | $-190.10M | $-59.24M |
| EPS (diluted) | $-0.20 | $-0.52 | $-0.94 | $-2.43 | $-0.78 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$1.35+113.95%
- Strong buy 0
- Buy 0
- Hold 1
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.06 vs —
LAB news
All LAB news- Standard BioTools Stockholders Approve All Proposals Related to Merger with Treeline Biosciences and Sale of Mass Cytometry BusinessGlobeNewswire
- Labrador Gold Announces Commencement of Strategic ReviewGlobeNewswire
- ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark ScientificGlobeNewswire
- Labrador Gold Announces Management AdditionsGlobeNewswire
- Labrador Gold Closes $2.1 Million First Tranche of Non-Brokered Private Placement and Announces Appointment of Raymond D. Harari as DirectorGlobeNewswire
- Labrador Gold Announces Upsize of Non-Brokered Private Placement to up to $7 MillionGlobeNewswire
- Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch.NasdaqPTGX, JNJ, LAB, XNCR
Standard BioTools peers
Industrials sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NAUTNautilus Biotechnology Inc. | 2.12 | -2.30% | $270.03M | vs LAB |
| QTRXQuanterix Corporation | 1.96 | -3.45% | $93.06M | vs LAB |
| SEERSeer Inc. Class A | 1.36 | -1.81% | $75.91M | vs LAB |
| HBIOHarvard Bioscience Inc. | 8.66 | -0.23% | $39.60M | vs LAB |
| RPIDRapid Micro Biosystems Inc. Class A | 0.735 | -0.04% | $37.37M | vs LAB |
| PRPOPrecipio Inc. | 17.35 | -6.17% | $31.11M | vs LAB |
| EYPTEyePoint Inc. | 0.2342 | -11.36% | $26.65M | vs LAB |
| CIRCCircle8 Group Inc. | 0.1361 | -12.25% | $15.99M | vs LAB |
Indexes, lists and sector
Standard BioTools stock FAQ
What is Standard BioTools's stock price today?
LAB last traded at $0.631 as of Nov 20, 4:00 PM EST, up 2.82% on the day. Prices are delayed at least 15 minutes.
Who is Standard BioTools's CEO?
Dr. Michael Egholm Ph.D. is the chief executive officer of Standard BioTools Inc., which has about 385 employees.
What is the LAB 52-week high?
The 52-week high for LAB is $1.72 and the 52-week low is $0.39. The stock is currently 63.3% below its high.